<< Back To Search

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05317416
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to see how well they work together in treating the disease. Here are some key points about the study:
  • The treatment involves a combination of existing therapies that have shown promise in previous studies.
  • Patients will receive the treatment in a structured way, allowing researchers to monitor its effectiveness closely.
  • This study is unique because it aims to understand how different therapies can work together to improve patient outcomes.
  • Participants will be closely observed for any side effects and overall health improvements.
  • The goal is to find a more effective treatment strategy that could lead to better management of the disease.
Overall, this study represents an important step in finding new ways to help patients manage their condition and improve their quality of life.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: